CAS 334969-03-8: Benzoic acid,4-[(1E)-2-[[(4-chlorophenyl)methyl]sulfonyl]ethenyl]-

Recilisib is a Chinese herb that has been shown to have the potential to be used as a biomarker for cancer. In addition, it can be used as a pharmaceutical drug for the treatment of cancer. Recilisib is an anti-tumor agent that induces pro-apoptotic protein production in cells and prevents cell cycle progression. Recilisib also inhibits radiation-induced toxicity in epidermal cells and increases the viability of cancer cells by inhibiting cell factor expression. The effect of Recilisib on stem cells has not been studied, but it has been shown to increase fetal bovine serum cell viability and inhibit pentobarbital sodium induced sleep in rats.

Recilisib (ON 01210) is a radioprotectant,can activate AKT, PI3K activities in cells.

Recilisib